687 related articles for article (PubMed ID: 26754641)
1. Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status.
Piccio L; Deming Y; Del-Águila JL; Ghezzi L; Holtzman DM; Fagan AM; Fenoglio C; Galimberti D; Borroni B; Cruchaga C
Acta Neuropathol; 2016 Jun; 131(6):925-33. PubMed ID: 26754641
[TBL] [Abstract][Full Text] [Related]
2. Early increase of CSF sTREM2 in Alzheimer's disease is associated with tau related-neurodegeneration but not with amyloid-β pathology.
Suárez-Calvet M; Morenas-Rodríguez E; Kleinberger G; Schlepckow K; Araque Caballero MÁ; Franzmeier N; Capell A; Fellerer K; Nuscher B; Eren E; Levin J; Deming Y; Piccio L; Karch CM; Cruchaga C; Shaw LM; Trojanowski JQ; Weiner M; Ewers M; Haass C;
Mol Neurodegener; 2019 Jan; 14(1):1. PubMed ID: 30630532
[TBL] [Abstract][Full Text] [Related]
3. The
Deming Y; Filipello F; Cignarella F; Cantoni C; Hsu S; Mikesell R; Li Z; Del-Aguila JL; Dube U; Farias FG; Bradley J; Budde J; Ibanez L; Fernandez MV; Blennow K; Zetterberg H; Heslegrave A; Johansson PM; Svensson J; Nellgård B; Lleo A; Alcolea D; Clarimon J; Rami L; Molinuevo JL; Suárez-Calvet M; Morenas-Rodríguez E; Kleinberger G; Ewers M; Harari O; Haass C; Brett TJ; Benitez BA; Karch CM; Piccio L; Cruchaga C
Sci Transl Med; 2019 Aug; 11(505):. PubMed ID: 31413141
[TBL] [Abstract][Full Text] [Related]
4. TREM2 brain transcript-specific studies in AD and TREM2 mutation carriers.
Del-Aguila JL; Benitez BA; Li Z; Dube U; Mihindukulasuriya KA; Budde JP; Farias FHG; Fernández MV; Ibanez L; Jiang S; Perrin RJ; Cairns NJ; Morris JC; Harari O; Cruchaga C
Mol Neurodegener; 2019 May; 14(1):18. PubMed ID: 31068200
[TBL] [Abstract][Full Text] [Related]
5. Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease.
Heslegrave A; Heywood W; Paterson R; Magdalinou N; Svensson J; Johansson P; Öhrfelt A; Blennow K; Hardy J; Schott J; Mills K; Zetterberg H
Mol Neurodegener; 2016 Jan; 11():3. PubMed ID: 26754172
[TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup.
Woollacott IOC; Nicholas JM; Heslegrave A; Heller C; Foiani MS; Dick KM; Russell LL; Paterson RW; Keshavan A; Fox NC; Warren JD; Schott JM; Zetterberg H; Rohrer JD
Alzheimers Res Ther; 2018 Aug; 10(1):79. PubMed ID: 30111356
[TBL] [Abstract][Full Text] [Related]
7. Variants in the MS4A cluster interact with soluble TREM2 expression on biomarkers of neuropathology.
Winfree RL; Nolan E; Dumitrescu L; Blennow K; Zetterberg H; Gifford KA; Pechman KR; Seto M; Petyuk VA; Wang Y; Schneider J; Bennett DA; Jefferson AL; Hohman TJ;
Mol Neurodegener; 2024 May; 19(1):41. PubMed ID: 38760857
[TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid soluble TREM2 in aging and Alzheimer's disease.
Henjum K; Almdahl IS; Årskog V; Minthon L; Hansson O; Fladby T; Nilsson LN
Alzheimers Res Ther; 2016 Apr; 8(1):17. PubMed ID: 27121148
[TBL] [Abstract][Full Text] [Related]
9. Proteo-genomics of soluble TREM2 in cerebrospinal fluid provides novel insights and identifies novel modulators for Alzheimer's disease.
Wang L; Nykänen NP; Western D; Gorijala P; Timsina J; Li F; Wang Z; Ali M; Yang C; Liu M; Brock W; Marquié M; Boada M; Alvarez I; Aguilar M; Pastor P; Ruiz A; Puerta R; Orellana A; Rutledge J; Oh H; Greicius MD; Le Guen Y; Perrin RJ; Wyss-Coray T; Jefferson A; Hohman TJ; Graff-Radford N; Mori H; Goate A; Levin J; Sung YJ; Cruchaga C
Mol Neurodegener; 2024 Jan; 19(1):1. PubMed ID: 38172904
[TBL] [Abstract][Full Text] [Related]
10. Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers.
Ashton NJ; Suárez-Calvet M; Heslegrave A; Hye A; Razquin C; Pastor P; Sanchez-Valle R; Molinuevo JL; Visser PJ; Blennow K; Hodges AK; Zetterberg H
Alzheimers Res Ther; 2019 Nov; 11(1):94. PubMed ID: 31779670
[TBL] [Abstract][Full Text] [Related]
11. sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers.
Suárez-Calvet M; Kleinberger G; Araque Caballero MÁ; Brendel M; Rominger A; Alcolea D; Fortea J; Lleó A; Blesa R; Gispert JD; Sánchez-Valle R; Antonell A; Rami L; Molinuevo JL; Brosseron F; Traschütz A; Heneka MT; Struyfs H; Engelborghs S; Sleegers K; Van Broeckhoven C; Zetterberg H; Nellgård B; Blennow K; Crispin A; Ewers M; Haass C
EMBO Mol Med; 2016 May; 8(5):466-76. PubMed ID: 26941262
[TBL] [Abstract][Full Text] [Related]
12. CSF soluble TREM2 as a measure of immune response along the Alzheimer's disease continuum.
Rauchmann BS; Schneider-Axmann T; Alexopoulos P; Perneczky R;
Neurobiol Aging; 2019 Feb; 74():182-190. PubMed ID: 30458365
[TBL] [Abstract][Full Text] [Related]
13. Genome-wide association study identifies Alzheimer's risk variant in MS4A6A influencing cerebrospinal fluid sTREM2 levels.
Hou XH; Bi YL; Tan MS; Xu W; Li JQ; Shen XN; Dou KX; Tan CC; Tan L; ; Yu JT
Neurobiol Aging; 2019 Dec; 84():241.e13-241.e20. PubMed ID: 31204042
[TBL] [Abstract][Full Text] [Related]
14. Genome-Wide Association Studies for Cerebrospinal Fluid Soluble TREM2 in Alzheimer's Disease.
Liu C; Yu J
Front Aging Neurosci; 2019; 11():297. PubMed ID: 31708768
[TBL] [Abstract][Full Text] [Related]
15. Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study.
Morenas-Rodríguez E; Li Y; Nuscher B; Franzmeier N; Xiong C; Suárez-Calvet M; Fagan AM; Schultz S; Gordon BA; Benzinger TLS; Hassenstab J; McDade E; Feederle R; Karch CM; Schlepckow K; Morris JC; Kleinberger G; Nellgard B; Vöglein J; Blennow K; Zetterberg H; Ewers M; Jucker M; Levin J; Bateman RJ; Haass C;
Lancet Neurol; 2022 Apr; 21(4):329-341. PubMed ID: 35305339
[TBL] [Abstract][Full Text] [Related]
16. Soluble TREM2 changes during the clinical course of Alzheimer's disease: A meta-analysis.
Liu D; Cao B; Zhao Y; Huang H; McIntyre RS; Rosenblat JD; Zhou H
Neurosci Lett; 2018 Nov; 686():10-16. PubMed ID: 30171911
[TBL] [Abstract][Full Text] [Related]
17. Soluble TREM2 and biomarkers of central and peripheral inflammation in neurodegenerative disease.
Bekris LM; Khrestian M; Dyne E; Shao Y; Pillai JA; Rao SM; Bemiller SM; Lamb B; Fernandez HH; Leverenz JB
J Neuroimmunol; 2018 Jun; 319():19-27. PubMed ID: 29685286
[TBL] [Abstract][Full Text] [Related]
18. Early changes in CSF sTREM2 in dominantly inherited Alzheimer's disease occur after amyloid deposition and neuronal injury.
Suárez-Calvet M; Araque Caballero MÁ; Kleinberger G; Bateman RJ; Fagan AM; Morris JC; Levin J; Danek A; Ewers M; Haass C;
Sci Transl Med; 2016 Dec; 8(369):369ra178. PubMed ID: 27974666
[TBL] [Abstract][Full Text] [Related]
19. TREM2 ectodomain and its soluble form in Alzheimer's disease.
Yang J; Fu Z; Zhang X; Xiong M; Meng L; Zhang Z
J Neuroinflammation; 2020 Jul; 17(1):204. PubMed ID: 32635934
[TBL] [Abstract][Full Text] [Related]
20. Dynamic changes of CSF sTREM2 in preclinical Alzheimer's disease: the CABLE study.
Ma LZ; Tan L; Bi YL; Shen XN; Xu W; Ma YH; Li HQ; Dong Q; Yu JT
Mol Neurodegener; 2020 Apr; 15(1):25. PubMed ID: 32276587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
